MYODM
Commercial- Indications
- Myotonic dystrophy type 1, Steinert disease
Company intelligence / Profile preview
Myogem Health Company
Mollet del Vallès, Barcelona, Spainmyogemhealth.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Commercial
01
Overview
The company has developed MYODM™, a synergistic combination of theobromine and caffeine that has shown ability to reduce the number of foci aggregates per cell and increase MBNL1 at transcript and protein levels. Clinical trial NCT04634682 is evaluating MYODM™'s effect on quality of life, fatigue, and hypersomnia in adult DM1 patients.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesnutritional supplements
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Myogem Health Company.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myogem Health Company.